Communiqués Scancell Holdings plc

Actions

Temps Différé London S.E. Autres places de cotation 09:24:09 12/06/2024			Varia. 5j.	Varia. 1 janv.
10,3 ^GBX	+9,52 %		+5,59 %	-1,95 %

30/05	Scancell obtient l'approbation du Royaume-Uni pour ajouter une cohorte d'expansion à l'essai de vaccin contre le cancer	MT
30/05	National World estime que les resultats de l'exercice sont conformes aux attentes	RE

Scancell : Interim Report 31st October 2023	21/05	PU
Scancell CEO hails "exciting" high response rate to melanoma treatment	20/09/23	AQ
Scancell : Positive Data for SCIB1, 19th September 2023	19/09/23	PU
Scancell : SCIB1 SCOPE study shows a striking 82% ORR	19/09/23	PU
Scancell : Upcoming SCIB1 data could provide first proof of concept	06/09/23	PU
Scancell Holdings "well-financed" and continuing to pursue deals	11/07/23	AQ
Scancell : Modi-1 successful in first part of Phase I/II trial	21/02/23	PU
Scancell : a leader in antibody and vaccine technology platforms	15/02/23	PU
Scancell : Interim Report 31st October 2022	25/01/23	PU
Scancell : AGM Presentation 2022	22/11/22	PU
Scancell : Notice of Annual General Meeting November 2022	28/10/22	PU
Scancell : A fresh impetus in delivering immune-oncology vaccines	13/04/22	PU
Scancell : Interim Report 31st October 2021	26/01/22	PU
Annual Report 30th April 2021	29/10/21	PU
Scancell : COVIDITY programme to start Phase I in H221	22/06/21	PU
Scancell : H121 results highlight shift to delivery and execution January 2021	29/01/21	PU
Scancell : Interim Report 31st October 2020	29/01/21	PU
Scancell : Redmile funding releases the brakes	18/11/20	PU
Scancell : Notice of Annual General Meeting November 2020	21/10/20	PU
Scancell : Annual Report 30th April 2020	16/10/20	PU

Aucun résultat pour cette recherche